Berg D - Search Results

1

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B. Berg D, et al. Mov Disord. 2011 Jun;26(7):1243-50. doi: 10.1002/mds.23616. Epub 2011 Apr 11. Mov Disord. 2011. PMID: 21484867 Clinical Trial.

2

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Berg D, Merz B, Reiners K, Naumann M, Becker G. Berg D, et al. Mov Disord. 2005 Mar;20(3):383-5. doi: 10.1002/mds.20311. Mov Disord. 2005. PMID: 15486999

3

Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients.

Berg D, Niwar M, Maass S, Zimprich A, Möller JC, Wuellner U, Schmitz-Hübsch T, Klein C, Tan EK, Schöls L, Marsh L, Dawson TM, Janetzky B, Müller T, Woitalla D, Kostic V, Pramstaller PP, Oertel WH, Bauer P, Krueger R, Gasser T, Riess O. Berg D, et al. Mov Disord. 2005 Sep;20(9):1191-4. doi: 10.1002/mds.20504. Mov Disord. 2005. PMID: 15895422

4

Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.

Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Schweitzer KJ, et al. Among authors: berg d. Mov Disord. 2006 Jan;21(1):94-8. doi: 10.1002/mds.20669. Mov Disord. 2006. PMID: 16114024

5

Iron metabolism in Parkinsonian syndromes.

Berg D, Hochstrasser H. Berg D, et al. Mov Disord. 2006 Sep;21(9):1299-310. doi: 10.1002/mds.21020. Mov Disord. 2006. PMID: 16817199 Review.

6

Predictive value of transcranial sonography in the diagnosis of Parkinson's disease.

Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Prestel J, et al. Among authors: berg d. Mov Disord. 2006 Oct;21(10):1763-5. doi: 10.1002/mds.21054. Mov Disord. 2006. PMID: 16874758 Clinical Trial.

7

Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome.

Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Godau J, et al. Among authors: berg d. Mov Disord. 2007 Jan 15;22(2):187-92. doi: 10.1002/mds.21230. Mov Disord. 2007. PMID: 17133515

8

Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Müller A, Gasser T, Berg D. Schweitzer KJ, et al. Among authors: berg d. J Neural Transm (Vienna). 2007 Sep;114(9):1167-71. doi: 10.1007/s00702-007-0725-5. Epub 2007 Apr 20. J Neural Transm (Vienna). 2007. PMID: 17446999

9

Sonographic abnormalities of brainstem structures in restless legs syndrome.

Godau J, Wevers AK, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D. Godau J, et al. Among authors: berg d. Sleep Med. 2008 Oct;9(7):782-9. doi: 10.1016/j.sleep.2007.09.001. Epub 2007 Nov 19. Sleep Med. 2008. PMID: 18024170

10

Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population.

Liepelt I, Wendt A, Schweitzer KJ, Wolf B, Godau J, Gaenslen A, Bruessel T, Berg D. Liepelt I, et al. Among authors: berg d. J Neural Transm (Vienna). 2008 Jul;115(7):993-9. doi: 10.1007/s00702-008-0043-6. Epub 2008 Mar 27. J Neural Transm (Vienna). 2008. PMID: 18368284

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,414 results

Search Page

Filters